FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903482389> ?p ?o ?g. }

• W2903482389 endingPage "388" @default.
• W2903482389 startingPage "376" @default.
• W2903482389 abstract "Abstract Tumor cells exhibit altered lipid metabolism compared with normal cells. Cell signaling kinases are important for regulating lipid synthesis and energy storage. How upstream kinases regulate lipid content, versus direct targeting of lipid-metabolizing enzymes, is currently unexplored. We evaluated intracellular lipid concentrations in prostate and breast tumor spheroids, treated with drugs directly inhibiting metabolic enzymes fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), diacylglyceride acyltransferase (DGAT), and pyruvate dehydrogenase kinase (PDHK), or cell signaling kinase enzymes PI3K, AKT, and mTOR with lipidomic analysis. We assessed whether baseline lipid profiles corresponded to inhibitors' effectiveness in modulating lipid profiles in three-dimensional (3D) growth and their relationship to therapeutic activity. Inhibitors against PI3K, AKT, and mTOR significantly inhibited MDA-MB-468 and PC3 cell growth in two-dimensional (2D) and 3D spheroid growth, while moderately altering lipid content. Conversely, metabolism inhibitors against FASN and DGAT altered lipid content most effectively, while only moderately inhibiting growth compared with kinase inhibitors. The FASN and ACC inhibitors' effectiveness in MDA-MB-468, versus PC3, suggested the former depended more on synthesis, whereas the latter may salvage lipids. Although baseline lipid profiles did not predict growth effects, lipid changes on therapy matched the growth effects of FASN and DGAT inhibitors. Several phospholipids, including phosphatidylcholine, were also upregulated following treatment, possibly via the Kennedy pathway. As this promotes tumor growth, combination studies should include drugs targeting it. Two-dimensional drug screening may miss important metabolism inhibitors or underestimate their potency. Clinical studies should consider serial measurements of tumor lipids to prove target modulation. Pretherapy tumor classification by de novo lipid synthesis versus uptake may help demonstrate efficacy." @default.
• W2903482389 created "2018-12-11" @default.
• W2903482389 creator A5000153144 @default.
• W2903482389 creator A5006778176 @default.
• W2903482389 creator A5009480530 @default.
• W2903482389 creator A5011978635 @default.
• W2903482389 creator A5018317846 @default.
• W2903482389 creator A5027660695 @default.
• W2903482389 creator A5052903538 @default.
• W2903482389 creator A5057710096 @default.
• W2903482389 creator A5077374712 @default.
• W2903482389 creator A5079633934 @default.
• W2903482389 creator A5090126935 @default.
• W2903482389 creator A5090750181 @default.
• W2903482389 creator A5091741754 @default.
• W2903482389 date "2019-02-01" @default.
• W2903482389 modified "2023-09-27" @default.
• W2903482389 title "3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers" @default.
• W2903482389 cites W1756026368 @default.
• W2903482389 cites W1884217239 @default.
• W2903482389 cites W1975701262 @default.
• W2903482389 cites W1977222014 @default.
• W2903482389 cites W1984630839 @default.
• W2903482389 cites W1985311405 @default.
• W2903482389 cites W1996575904 @default.
• W2903482389 cites W2003564623 @default.
• W2903482389 cites W2014253236 @default.
• W2903482389 cites W2017399995 @default.
• W2903482389 cites W2022853846 @default.
• W2903482389 cites W2027705428 @default.
• W2903482389 cites W2044515618 @default.
• W2903482389 cites W2057001750 @default.
• W2903482389 cites W2058168165 @default.
• W2903482389 cites W2064318855 @default.
• W2903482389 cites W2070732456 @default.
• W2903482389 cites W2077328356 @default.
• W2903482389 cites W2083166156 @default.
• W2903482389 cites W2091532850 @default.
• W2903482389 cites W2094093571 @default.
• W2903482389 cites W2095707070 @default.
• W2903482389 cites W2101572834 @default.
• W2903482389 cites W2102416115 @default.
• W2903482389 cites W2116516144 @default.
• W2903482389 cites W2125872855 @default.
• W2903482389 cites W2139126860 @default.
• W2903482389 cites W2141125222 @default.
• W2903482389 cites W2148378558 @default.
• W2903482389 cites W2150494760 @default.
• W2903482389 cites W2152675473 @default.
• W2903482389 cites W2220436777 @default.
• W2903482389 cites W2314067388 @default.
• W2903482389 cites W2323791142 @default.
• W2903482389 cites W2403922329 @default.
• W2903482389 cites W2472687470 @default.
• W2903482389 cites W2594862518 @default.
• W2903482389 cites W2605772872 @default.
• W2903482389 cites W2621936089 @default.
• W2903482389 cites W2769383666 @default.
• W2903482389 cites W2771932126 @default.
• W2903482389 cites W2773870182 @default.
• W2903482389 cites W2789281724 @default.
• W2903482389 cites W4241534679 @default.
• W2903482389 cites W4243903519 @default.
• W2903482389 doi "https://doi.org/10.1158/1535-7163.mct-17-0857" @default.
• W2903482389 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6611711" @default.
• W2903482389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30478149" @default.
• W2903482389 hasPublicationYear "2019" @default.
• W2903482389 type Work @default.
• W2903482389 sameAs 2903482389 @default.
• W2903482389 citedByCount "14" @default.
• W2903482389 countsByYear W29034823892019 @default.
• W2903482389 countsByYear W29034823892020 @default.
• W2903482389 countsByYear W29034823892021 @default.
• W2903482389 countsByYear W29034823892022 @default.
• W2903482389 countsByYear W29034823892023 @default.
• W2903482389 crossrefType "journal-article" @default.
• W2903482389 hasAuthorship W2903482389A5000153144 @default.
• W2903482389 hasAuthorship W2903482389A5006778176 @default.
• W2903482389 hasAuthorship W2903482389A5009480530 @default.
• W2903482389 hasAuthorship W2903482389A5011978635 @default.
• W2903482389 hasAuthorship W2903482389A5018317846 @default.
• W2903482389 hasAuthorship W2903482389A5027660695 @default.
• W2903482389 hasAuthorship W2903482389A5052903538 @default.
• W2903482389 hasAuthorship W2903482389A5057710096 @default.
• W2903482389 hasAuthorship W2903482389A5077374712 @default.
• W2903482389 hasAuthorship W2903482389A5079633934 @default.
• W2903482389 hasAuthorship W2903482389A5090126935 @default.
• W2903482389 hasAuthorship W2903482389A5090750181 @default.
• W2903482389 hasAuthorship W2903482389A5091741754 @default.
• W2903482389 hasBestOaLocation W29034823891 @default.
• W2903482389 hasConcept C181199279 @default.
• W2903482389 hasConcept C184235292 @default.
• W2903482389 hasConcept C185592680 @default.
• W2903482389 hasConcept C25095133 @default.
• W2903482389 hasConcept C2776941171 @default.
• W2903482389 hasConcept C4733338 @default.
• W2903482389 hasConcept C48289651 @default.
• W2903482389 hasConcept C55493867 @default.

• next